-
Good news for breast cancer patients!
Time of Update: 2022-04-23
Trastuzumab, Emmett, constantly explores the cure and survival of breast cancer patients. Using medical evidence to provide a strong backing for clinical diagnosis and treatment of early breast cance
-
5 pictures of gastric cancer staging
Time of Update: 2022-04-23
TNM staging of gastric cancerThe most commonly used staging system for gastric cancer is the American Joint Committee on Cancer (AJCC) TNM staging system .
The most commonly used staging system for gastric cancer is the American Joint Committee on Cancer (AJCC) TNM staging system .
-
JNCCN: Quality of life is closely related to the prognosis of gastric cancer patients!
Time of Update: 2022-04-23
In conclusion, in the CRITICS trial, compared with the chemoradiotherapy group, the postoperative physiological function of the patients in the chemotherapy group was significantly improved, and the dysphagia was significantly reduced .
-
J Thorac Oncol: Efficacy of lorlatinib in Chinese patients with previously treated ALK-positive advanced or metastatic NSCLC
Time of Update: 2022-04-23
The study is an open-label, dual-cohort Phase 2 clinical study to evaluate the efficacy of lorlatinib (lorlatinib) in Chinese patients with previously treated ALK-positive advanced or metastatic NSCLC .
-
Nature Biotechnology: Concealing the sky, putting on an "invisibility cloak" for bacteria, allowing them to bypass the immune system to attack cancer cells
Time of Update: 2022-04-23
When we hear the word "bacteria", we are more likely to associate dirty things such as sewage and rotten food in our subconscious mind . But in fact, there are billions of symbiotic flora in our body
-
J Thorac Oncol: Pooled analysis of 5 RCTs suggests that proton pump inhibitor (PPIs) use reduces the efficacy of atezolizumab treatment
Time of Update: 2022-04-23
Therefore, the Australian team conducted a pooled analysis study to assess whether antibiotics or PPIs affected the efficacy of atezolizumab ( atezolizumab ) in patients with advanced non-small cell lung cancer (NSCLC) .
-
Front Oncol: Efficacy of low-dose nab-paclitaxel combined with PD-1 inhibitor (tislelizumab) in elderly patients with advanced non-small cell lung cancer (NSCLC)
Time of Update: 2022-04-23
Median PFS was significantly longer in patients with EGFR/ALK wild-type non-squamous NSCLC (11.
Median PFS was significantly longer in patients with EGFR/ALK wild-type non-squamous NSCLC (11.
Median PFS was significantly longer in patients with EGFR/ALK wild-type non-squamous NSCLC (11.
-
Eur J Cancer: Surveillance of Melanoma High-Risk Patients: Can Convolutional Neural Networks Replace Sequential Digital Dermoscopy Strategies?
Time of Update: 2022-04-23
Eur J Cancer 2022 01;160Winkler JK, Tschandl P, Toberer F, Monitoring patients at risk for melanoma: May convolutional neural networks replace the strategy of sequential digital dermoscopy?
-
Front Oncol: Exploring risk factors and prognosis of gastric adenocarcinoma with bone metastases based on a large population cohort
Time of Update: 2022-04-23
Taken together, studies have shown that, in GaC patients, bone metastasis is associated with various clinicopathological factors, including age, ethnicity, tumor location, histology, differentiation, and metastasis at other sites .
-
Sugar-free ≠ healthy!
Time of Update: 2022-04-23
Figure 1 Research results (Source: PLOS MEDICINE )Figure 1 Research results (Source: PLOS MEDICINE )In this study, researchers followed 102,865 adults from NutriNet-Santé , France ( 2009-2021 ) with 24 -hour dietary records for dietary intake and consumption of artificial sweeteners, adjusted for age Cox proportional hazards model was used to evaluate the association between artificial sweeteners and the incidence of cancer after related factors such as gender, education level, medical history, and life>.
-
J Clin Oncol: Early clinical features of Gorlin syndrome predict later severity
Time of Update: 2022-04-23
The most characteristic clinical feature of Gorlin syndrome is a high lifetime incidence of basal cell carcinoma (BCC), skeletal abnormalities (SA), and other extracutaneous tumors .
-
Science Advances: Implanting a "cell drug factory" in the body to remove cancer cells in 6 days, and clinical trials will be launched this year
Time of Update: 2022-04-23
Science Advances Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumorsThe study developed an in vivo "cellular drug factory" that uses microcapsules based on the natural material alginate to encapsulate engineered human retinal pigment epithelial (RPE) cells that stably express high levels of IL-2 and implant them near tumors.
-
Front Oncol: The prognostic role of the number of resected lymph nodes in stage II small bowel adenocarcinoma (SBA) based on the SEER database
Time of Update: 2022-04-23
According to the National Comprehensive Cancer Network (NCCN) guidelines, insufficient examination of lymph nodes (LNs) (<5 duodenum and <8 primary sites of jejunum/ileum) is one of the high-risk factors for stage II patients, and adjuvant chemotherapy is recommended .
-
JAMA Oncol: Generic HD201 is as effective as trastuzumab in ERBB2-positive breast cancer!
Time of Update: 2022-04-23
A total of 502 patients with definitively diagnosed ERBB2-positive early breast cancer were enrolled and randomized into two groups to receive HD201 or trastuzumab 8 courses of anti-treatment, all patients received 4 courses of docetaxel at the same time, followed by 4 courses of epirubicin and cyclophosphamide, and then received surgery; postoperatively, patients received 10 courses of HD201 or Trastuzumab therapy .
-
Cohort study of more than 100,000 people: avoiding obesity and getting cancer?
Time of Update: 2022-04-23
Therefore, the purpose of this study was to investigate the intake of artificial sweeteners (total intake and most common intakes, based on detailed dietary data including industrial product names/brands) in a large population-based NutriNet-Santé cohort ingested intake) and cancer risk (total intake and site of most common cancer) .
-
J clin oncol: Risk of peritoneal cancer after salpingo-oophorectomy in BRCA1/2 pathogenic variant carriers
Time of Update: 2022-04-23
The primary outcome measures were the hazard ratio of developing peritoneal cancer in BRCA1/2 pathogenic variant carriers with and without STIC at the time of RRSO, and the risk of peritoneal cancer at 5 and 10 years after surgery .
-
Cancer Discovery: Novel immune checkpoint: can be used to enhance T cells against cancer, and also allows CAR-T to fight solid tumors
Time of Update: 2022-04-23
Cancer Discovery PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor ImmunityThe study found that inhibiting protein tyrosine phosphatase 1B (PTP1B) on T cells mobilized the body's immune response to cancer and helped suppress tumor growth .
-
Oncologist: Combination therapy of cetuximab + irinotecan + bevacizumab fails to improve PFS but improves OS in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)
Time of Update: 2022-04-23
Recently, a related study was published in the journal Oncologist, in patients with irinotecan-refractory metastatic colorectal cancer (mCRC) who had not previously received anti-EGFR therapy, the addition of cetuximab + irinotecan.
-
Int J Urol: Which is better, radical prostatectomy or external radiation therapy + androgen deprivation therapy in patients with clinical T3b prostate cancer?
Time of Update: 2022-04-23
Definite treatments for prostate cancer include radical prostatectomy and External radiation therapy, the optimal treatment of prostate tumors is currently unknown due to the lack of clear and well-defined randomized controlled trialsHere, researchers from Hallym University Dongtan Sacred Heart Hospital in South Korea compared the oncological outcomes of patients with clinical T3b prostate cancer who received either radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (HT + RT) .
-
Nat Rev Clin Oncol: A New Strategy for the Treatment of Advanced Gastrointestinal Stromal Tumors
Time of Update: 2022-04-23
background:background:Gastrointestinal stromal tumor (GIST), the most common form of sarcoma, was first recognized as a distinct pathological entity in the 1990s, and patients with advanced disease have a very poor prognosis due to the lack of effective medical therapy .